These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 33331183

  • 1. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment.
    Vermersch P, Galazka A, Dangond F, Damian D, Wong SL, Jack D, Harty G.
    Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan KW, Rieckmann P, Comi G, Dangond F, Hicking C, Vermersch P.
    Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
    [Abstract] [Full Text] [Related]

  • 3. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S, CLARITY study group.
    Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
    [Abstract] [Full Text] [Related]

  • 4. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P, Martinelli V, Pfleger C, Rieckmann P, Alonso-Magdalena L, Galazka A, Dangond F, Phillips L.
    Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
    [Abstract] [Full Text] [Related]

  • 5. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
    Giovannoni G, Comi G, Rammohan K, Rieckmann P, Dangond F, Keller B, Jack D, Vermersch P.
    Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
    [Abstract] [Full Text] [Related]

  • 6. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
    De Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist T, Coyle PK, Dangond F, Keller B, Alexandri N, Galazka A.
    Mult Scler; 2022 Jan; 28(1):111-120. PubMed ID: 33969750
    [Abstract] [Full Text] [Related]

  • 7. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS, Pontieri L, Joensen H, Heick A, Rasmussen PV, Schäfer J, Ratzer R, Pihl CE, Sellebjerg F, Magyari M.
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [Abstract] [Full Text] [Related]

  • 8. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
    Berardi A, Siddiqui MK, Treharne C, Harty G, Wong SL.
    Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
    [Abstract] [Full Text] [Related]

  • 9. Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study.
    Rammohan K, Giovannoni G, Comi G, Cook S, Rieckmann P, Soelberg Sørensen P, Vermersch P, Hamlett A, Kurukulasuriya N, CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group.
    Mult Scler Relat Disord; 2012 Jan; 1(1):49-54. PubMed ID: 25876451
    [Abstract] [Full Text] [Related]

  • 10. Cladribine Tablets: A Review in Relapsing MS.
    Deeks ED.
    CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
    [Abstract] [Full Text] [Related]

  • 11. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
    Bartosik-Psujek H, Kaczyński Ł, Górecka M, Rolka M, Wójcik R, Zięba P, Kaczor M.
    Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
    [Abstract] [Full Text] [Related]

  • 12. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
    Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Greenberg S, Scott DA, Joyeux A, CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group.
    Clin Drug Investig; 2012 Jan 01; 32(1):15-27. PubMed ID: 22017519
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R, Harty G, Wong SL.
    J Med Econ; 2018 Jul 01; 21(7):676-686. PubMed ID: 29618273
    [Abstract] [Full Text] [Related]

  • 14. Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.
    Bell Gorrod H, Latimer NR, Damian D, Hettle R, Harty GT, Wong SL.
    Adv Ther; 2020 Jan 01; 37(1):225-239. PubMed ID: 31701485
    [Abstract] [Full Text] [Related]

  • 15. Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
    Brownlee WJ, Haghikia A, Hayward B, Waser N, Kayaniyil S, Khan Z, Duncan J, Millar S, Harty GT.
    Mult Scler Relat Disord; 2023 Aug 01; 76():104791. PubMed ID: 37343465
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
    Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Van Der Walt A, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Blanco Morgado Y, Spitaleri D, van Pesch V, Horakova D, Ampapa R, Patti F, Macdonell R, Al-Asmi A, Gerlach O, Oh J, Altintas A, Tundia N, Wong SL, Butzkueven H.
    Mult Scler; 2023 Feb 01; 29(2):221-235. PubMed ID: 36433775
    [Abstract] [Full Text] [Related]

  • 19. Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis.
    Tafazzoli A, Chavan A, Harty G, Moller J, Wong SL.
    Adv Ther; 2020 Sep 01; 37(9):3791-3806. PubMed ID: 32647909
    [Abstract] [Full Text] [Related]

  • 20. Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.
    Michels RE, de Fransesco M, Mahajan K, Hengstman GJD, Schiffers KMH, Budhia S, Harty G, Krol M.
    Appl Health Econ Health Policy; 2019 Dec 01; 17(6):857-873. PubMed ID: 31444659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.